These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 12359757)
41. Single-molecule study of lateral mobility of epidermal growth factor receptor 2/HER2 on activation. Xiao Z; Ma X; Jiang Y; Zhao Z; Lai B; Liao J; Yue J; Fang X J Phys Chem B; 2008 Apr; 112(13):4140-5. PubMed ID: 18324805 [TBL] [Abstract][Full Text] [Related]
42. Study of inhibition effect of herceptin on interaction between heregulin and erbB receptors HER3/HER2 by single-molecule force spectroscopy. Shi X; Xu L; Yu J; Fang X Exp Cell Res; 2009 Oct; 315(16):2847-55. PubMed ID: 19497323 [TBL] [Abstract][Full Text] [Related]
43. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Agus DB; Akita RW; Fox WD; Lewis GD; Higgins B; Pisacane PI; Lofgren JA; Tindell C; Evans DP; Maiese K; Scher HI; Sliwkowski MX Cancer Cell; 2002 Aug; 2(2):127-37. PubMed ID: 12204533 [TBL] [Abstract][Full Text] [Related]
44. An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin. Garner AP; Bialucha CU; Sprague ER; Garrett JT; Sheng Q; Li S; Sineshchekova O; Saxena P; Sutton CR; Chen D; Chen Y; Wang H; Liang J; Das R; Mosher R; Gu J; Huang A; Haubst N; Zehetmeier C; Haberl M; Elis W; Kunz C; Heidt AB; Herlihy K; Murtie J; Schuller A; Arteaga CL; Sellers WR; Ettenberg SA Cancer Res; 2013 Oct; 73(19):6024-35. PubMed ID: 23928993 [TBL] [Abstract][Full Text] [Related]
45. Expression of HER2 in human gastric cancer cells directly correlates with antitumor activity of a recombinant disulfide-stabilized anti-HER2 immunotoxin. Shinohara H; Morita S; Kawai M; Miyamoto A; Sonoda T; Pastan I; Tanigawa N J Surg Res; 2002 Feb; 102(2):169-77. PubMed ID: 11796015 [TBL] [Abstract][Full Text] [Related]
46. Modulation of HER3 is a marker of dynamic cell signaling in ovarian cancer: implications for pertuzumab sensitivity. Nagumo Y; Faratian D; Mullen P; Harrison DJ; Hasmann M; Langdon SP Mol Cancer Res; 2009 Sep; 7(9):1563-71. PubMed ID: 19737968 [TBL] [Abstract][Full Text] [Related]
47. Neuregulin receptor-mediated gene transfer by human epidermal growth factor receptor 2-targeted antibodies and neuregulin-1. Kern JA; Wakita R; Sliwkowski MX Cancer Gene Ther; 1999; 6(6):537-45. PubMed ID: 10608350 [TBL] [Abstract][Full Text] [Related]
48. Significant systemic therapeutic effects of high-LET immunoradiation by 212Pb-trastuzumab against prostatic tumors of androgen-independent human prostate cancer in mice. Tan Z; Chen P; Schneider N; Glover S; Cui L; Torgue J; Rixe O; Spitz HB; Dong Z Int J Oncol; 2012 Jun; 40(6):1881-8. PubMed ID: 22322558 [TBL] [Abstract][Full Text] [Related]
49. Attenuation of Ras signaling restores androgen sensitivity to hormone-refractory C4-2 prostate cancer cells. Bakin RE; Gioeli D; Bissonette EA; Weber MJ Cancer Res; 2003 Apr; 63(8):1975-80. PubMed ID: 12702591 [TBL] [Abstract][Full Text] [Related]
50. RG7116, a therapeutic antibody that binds the inactive HER3 receptor and is optimized for immune effector activation. Mirschberger C; Schiller CB; Schräml M; Dimoudis N; Friess T; Gerdes CA; Reiff U; Lifke V; Hoelzlwimmer G; Kolm I; Hopfner KP; Niederfellner G; Bossenmaier B Cancer Res; 2013 Aug; 73(16):5183-94. PubMed ID: 23780344 [TBL] [Abstract][Full Text] [Related]
51. Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers. Wilson TR; Lee DY; Berry L; Shames DS; Settleman J Cancer Cell; 2011 Aug; 20(2):158-72. PubMed ID: 21840482 [TBL] [Abstract][Full Text] [Related]
52. Dual EGFR/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3. Chen L; Mooso BA; Jathal MK; Madhav A; Johnson SD; van Spyk E; Mikhailova M; Zierenberg-Ripoll A; Xue L; Vinall RL; deVere White RW; Ghosh PM Clin Cancer Res; 2011 Oct; 17(19):6218-28. PubMed ID: 21844010 [TBL] [Abstract][Full Text] [Related]
53. HER3 is required for the maintenance of neuregulin-dependent and -independent attributes of malignant progression in prostate cancer cells. Soler M; Mancini F; Meca-Cortés O; Sánchez-Cid L; Rubio N; López-Fernández S; Lozano JJ; Blanco J; Fernández PL; Thomson TM Int J Cancer; 2009 Dec; 125(11):2565-75. PubMed ID: 19530240 [TBL] [Abstract][Full Text] [Related]
54. Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling. Mullen P; Cameron DA; Hasmann M; Smyth JF; Langdon SP Mol Cancer Ther; 2007 Jan; 6(1):93-100. PubMed ID: 17237269 [TBL] [Abstract][Full Text] [Related]
55. Her2 crosstalks with TrkA in a subset of prostate cancer cells: rationale for a guided dual treatment. Festuccia C; Gravina GL; Muzi P; Millimaggi D; Dolo V; Vicentini C; Ficorella C; Ricevuto E; Bologna M Prostate; 2009 Mar; 69(4):337-45. PubMed ID: 19016477 [TBL] [Abstract][Full Text] [Related]